Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

533 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Predictors of the response of HbA1c and body weight after SGLT2 inhibition.
Abe T, Matsubayashi Y, Yoshida A, Suganami H, Nojima T, Osawa T, Ishizawa M, Yamamoto M, Fujihara K, Tanaka S, Kaku K, Sone H. Abe T, et al. Among authors: nojima t. Diabetes Metab. 2018 Mar;44(2):172-174. doi: 10.1016/j.diabet.2017.10.003. Epub 2017 Nov 8. Diabetes Metab. 2018. PMID: 29128289 Clinical Trial. No abstract available.
Efficacy and Safety of Pemafibrate, a Novel Selective Peroxisome Proliferator-Activated Receptor α Modulator (SPPARMα): Pooled Analysis of Phase 2 and 3 Studies in Dyslipidemic Patients with or without Statin Combination.
Yamashita S, Arai H, Yokote K, Araki E, Matsushita M, Nojima T, Suganami H, Ishibashi S. Yamashita S, et al. Among authors: nojima t. Int J Mol Sci. 2019 Nov 6;20(22):5537. doi: 10.3390/ijms20225537. Int J Mol Sci. 2019. PMID: 31698825 Free PMC article. Clinical Trial.
Evaluation of Data Errors and Monitoring Activities in a Trial in Japan Using a Risk-Based Approach Including Central Monitoring and Site Risk Assessment.
Kondo H, Kamiyoshihara T, Fujisawa K, Nojima T, Tanigawa R, Fujiwara H, Suganami H, Hayashi Y, Yamaguchi T. Kondo H, et al. Among authors: nojima t. Ther Innov Regul Sci. 2021 Jul;55(4):841-849. doi: 10.1007/s43441-021-00286-9. Epub 2021 Apr 19. Ther Innov Regul Sci. 2021. PMID: 33876398 Free PMC article.
Effects of pemafibrate on glucose metabolism markers and liver function tests in patients with hypertriglyceridemia: a pooled analysis of six phase 2 and phase 3 randomized double-blind placebo-controlled clinical trials.
Yokote K, Yamashita S, Arai H, Araki E, Matsushita M, Nojima T, Suganami H, Ishibashi S. Yokote K, et al. Among authors: nojima t. Cardiovasc Diabetol. 2021 May 4;20(1):96. doi: 10.1186/s12933-021-01291-w. Cardiovasc Diabetol. 2021. PMID: 33947390 Free PMC article.
Randomised clinical trial: Pemafibrate, a novel selective peroxisome proliferator-activated receptor α modulator (SPPARMα), versus placebo in patients with non-alcoholic fatty liver disease.
Nakajima A, Eguchi Y, Yoneda M, Imajo K, Tamaki N, Suganami H, Nojima T, Tanigawa R, Iizuka M, Iida Y, Loomba R. Nakajima A, et al. Among authors: nojima t. Aliment Pharmacol Ther. 2021 Nov;54(10):1263-1277. doi: 10.1111/apt.16596. Epub 2021 Sep 16. Aliment Pharmacol Ther. 2021. PMID: 34528723 Free PMC article. Clinical Trial.
533 results